StockData
argenx SE logo

argenx SE (ARGX) stock

ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026Score 5/30
$947.52−3.43 (-0.36%)

Close on Nov 17, 2026Market cap –P/E 48.4Yield –

argenx operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was $1.05B. The highest annual figure on record is $1.05B in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.05B–
FY2024Dec 31, 2024-$21.65M–
FY2023Dec 31, 2023-$425.05M–
FY2022Dec 31, 2022-$720.34M–
FY2021Dec 31, 2021-$348.75M–
FY2020Dec 31, 2020-$477.62M–
FY2019Dec 31, 2019-$198.89M–
FY2018Dec 31, 2018-$81.85M–

More argenx figures

See a number that looks wrong?